Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients

Pirfenidone Therapy for Familial Pulmonary Fibrosis: A Real-Life Study

(2019) David Bennett et al.   LUNG

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

(2018) Ganesh Raghu et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON

(2018) Bruno Crestani et al.   Lancet Respiratory Medicine

Idiopathic Pulmonary Fibrosis (IPF): An Overview

(2018) Shaney Barratt et al.   Journal of Clinical Medicine

Idiopathic pulmonary fibrosis: a holistic approach to disease management in the antifibrotic age

(2017) Jonathon Shaw et al.   Journal of Thoracic Disease

Health-Related Quality of Life in Patients with Idiopathic Pulmonary Fibrosis

(2016) Susan E. Yount et al.   LUNG

Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis

(2016) Francesco Bonella et al.   RESPIRATION

Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients’ perspectives of the disease and treatment

(2016) Anne-Marie Russell et al.   BMC Pulmonary Medicine

Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis

(2016) Gareth Hughes et al.   Journal of Clinical Medicine

Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis

(2015) Marlies S. Wijsenbeek et al.   ADVANCES IN THERAPY

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline

(2015) Ganesh Raghu et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

A Role for Lung Retention in the Sense of Retronasal Smell

(2015) Justus V. Verhagen   Chemosensory Perception

Nintedanib in the treatment of idiopathic pulmonary fibrosis

(2015) Mariano E. Mazzei et al.   Therapeutic Advances in Respiratory Disease

Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events

(2014) Ulrich Costabel et al.   ADVANCES IN THERAPY

Perceptions, experiences and needs of patients with idiopathic pulmonary fibrosis

(2014) Annette Duck et al.   JOURNAL OF ADVANCED NURSING

Improvement in taste sensitivity following pulmonary rehabilitation in patients with chronic obstructive pulmonary disease

(2014) K Ito et al.   JOURNAL OF REHABILITATION MEDICINE

A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

(2014) Talmadge E. King et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis

(2014) Dominique Valeyre et al.   RESPIROLOGY

Epidemiology of idiopathic pulmonary fibrosis

(2013) Brett Ley et al.   Clinical Epidemiology

An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management

(2011) Ganesh Raghu et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

(2011) Paul W Noble et al.   LANCET

Effects of age, gender and chronic obstructive pulmonary disease on taste acuity

(2009) Laura Wardwell et al.   INTERNATIONAL JOURNAL OF FOOD SCIENCES AND NUTRITION

Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults

(2009) C.M. Rubino et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS